HUP0203408A2 - Eljárás hiperlipémia elleni preventív vagy terápiás hatóanyag tesztelésére - Google Patents

Eljárás hiperlipémia elleni preventív vagy terápiás hatóanyag tesztelésére

Info

Publication number
HUP0203408A2
HUP0203408A2 HU0203408A HUP0203408A HUP0203408A2 HU P0203408 A2 HUP0203408 A2 HU P0203408A2 HU 0203408 A HU0203408 A HU 0203408A HU P0203408 A HUP0203408 A HU P0203408A HU P0203408 A2 HUP0203408 A2 HU P0203408A2
Authority
HU
Hungary
Prior art keywords
testing
preventive
hyperlipemia
therapeutic
remedy
Prior art date
Application number
HU0203408A
Other languages
English (en)
Inventor
Yosuke Ando
Toshihiko Fujiwara
Hidehiko Furukawa
Hiroyoshi Horikoshi
Ryuta Koishi
Mitsuru Ono
Original Assignee
Sankyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co., Ltd. filed Critical Sankyo Co., Ltd.
Publication of HUP0203408A2 publication Critical patent/HUP0203408A2/hu
Publication of HUP0203408A3 publication Critical patent/HUP0203408A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A találmány hiperlipémia elleni preventív vagy terápiás hatóanyagtesztelésére alkalmas eljárásokra vonatkozik. Közelebbről, a találmánytárgyát eljárások képezik teszthatóanyagok hiperlipémia elleniterápiás vagy preventív hatásának tesztelésére a vér neutráliszsírkoncentrációjának szabályozásában résztvevő gének expressziósszintjének kimutatatásával, valamint az eljárásban alkalmazhatónukleinsavpróbák, láncindítók, és ellenanyagok. A találmány tárgyátképezik továbbá reagenskészletek hiperlipémia elleni terápiás vagypreventív hatóanyag tesztelésére. Ó
HU0203408A 1999-12-09 2000-12-08 Method of testing remedy or preventive for hyperlipemia HUP0203408A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34997699 1999-12-09
PCT/JP2000/008722 WO2001042499A1 (fr) 1999-12-09 2000-12-08 Procede d'essai d'agent curatif ou preventif de l'hyperlipemie

Publications (2)

Publication Number Publication Date
HUP0203408A2 true HUP0203408A2 (hu) 2003-01-28
HUP0203408A3 HUP0203408A3 (en) 2005-01-28

Family

ID=18407394

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0203408A HUP0203408A3 (en) 1999-12-09 2000-12-08 Method of testing remedy or preventive for hyperlipemia

Country Status (17)

Country Link
US (3) US20030017488A1 (hu)
EP (1) EP1239050A4 (hu)
KR (1) KR20020062652A (hu)
CN (1) CN1433482A (hu)
AU (1) AU768034B2 (hu)
BR (1) BR0016257A (hu)
CA (1) CA2390676A1 (hu)
CZ (1) CZ20021853A3 (hu)
HK (1) HK1045541A1 (hu)
HU (1) HUP0203408A3 (hu)
IL (1) IL149849A0 (hu)
MX (1) MXPA02005758A (hu)
NO (1) NO20022711L (hu)
PL (1) PL355666A1 (hu)
RU (1) RU2002115295A (hu)
WO (1) WO2001042499A1 (hu)
ZA (1) ZA200204432B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002235173A1 (en) * 2000-11-03 2002-05-15 Diadexus, Inc. Compositions and methods relating to prostate specific genes and proteins
IL159153A0 (en) * 2001-06-08 2004-06-01 Sankyo Co Methods for testing drugs for treating or preventing diseases such as hyperlipidemia
JPWO2003028445A1 (ja) * 2001-08-31 2005-01-13 大塚製薬株式会社 Ｔｓａ２３０６遺伝子欠損非ヒト動物
JP5484063B2 (ja) 2006-12-08 2014-05-07 レキシコン ファーマシューティカルズ インコーポレーテッド Ａｎｇｐｔｌ３に対するモノクローナル抗体
US8143600B2 (en) * 2008-02-18 2012-03-27 Visiongate, Inc. 3D imaging of live cells with ultraviolet radiation
US8653047B2 (en) 2010-01-08 2014-02-18 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
US20170037409A1 (en) 2013-12-24 2017-02-09 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
ES2844593T3 (es) 2014-05-01 2021-07-22 Ionis Pharmaceuticals Inc Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
BR112018003291A2 (pt) 2015-11-06 2018-09-25 Ionis Pharmaceuticals, Inc. modulando a expressão da apolipoproteina (a)
JOP20200050A1 (ar) 2017-09-14 2020-03-05 Arrowhead Pharmaceuticals Inc عوامل RNAi وتركيبات لتثبيط التعبير عن شبيه آنجيوبويتين 3 (ANGPTL3)، وطرق استخدام
CN109806632A (zh) * 2019-03-01 2019-05-28 中国科学院武汉物理与数学研究所 一种全血过滤装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058660A1 (en) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU3661199A (en) * 1998-04-27 1999-11-16 Zymogenetics Inc. Novel polypeptide growth factors and materials and methods for making them
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
AU4643699A (en) * 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
EP1161536A1 (en) * 1998-11-17 2001-12-12 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins
CA2347835A1 (en) * 1998-12-01 2000-06-08 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
EP1141284A2 (en) * 1998-12-22 2001-10-10 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US20020015950A1 (en) * 1999-07-07 2002-02-07 Karen Anne Jones Atherosclerosis-associated genes
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
JP2000325087A (ja) * 1999-05-21 2000-11-28 Otsuka Pharmaceut Co Ltd Ｔｓａ２３０６遺伝子
EP1210363A2 (en) * 1999-07-16 2002-06-05 Hyseq, Inc. Novel angiopoietin materials and methods
CA2375458A1 (en) * 1999-07-20 2001-01-25 Genentech, Inc. Compositions and methods for the treatment of immune related diseases

Also Published As

Publication number Publication date
CA2390676A1 (en) 2001-06-14
ZA200204432B (en) 2003-09-29
NO20022711L (no) 2002-08-08
EP1239050A1 (en) 2002-09-11
IL149849A0 (en) 2002-11-10
CN1433482A (zh) 2003-07-30
WO2001042499A1 (fr) 2001-06-14
CZ20021853A3 (cs) 2002-11-13
US20030211533A1 (en) 2003-11-13
NO20022711D0 (no) 2002-06-07
EP1239050A4 (en) 2004-07-21
US20030207251A1 (en) 2003-11-06
BR0016257A (pt) 2002-08-20
AU768034B2 (en) 2003-11-27
AU1887001A (en) 2001-06-18
RU2002115295A (ru) 2004-01-10
HUP0203408A3 (en) 2005-01-28
KR20020062652A (ko) 2002-07-26
HK1045541A1 (zh) 2002-11-29
MXPA02005758A (es) 2002-09-18
PL355666A1 (en) 2004-05-04
US20030017488A1 (en) 2003-01-23

Similar Documents

Publication Publication Date Title
HUP0203408A2 (hu) Eljárás hiperlipémia elleni preventív vagy terápiás hatóanyag tesztelésére
ATE488604T1 (de) System zum nachweis von polynukleotiden
ATE246356T1 (de) Vorrichtung zum vorhersagen von physiologischen messwerten
ATE438853T1 (de) Diagnostische testvorrichtung
ATE278803T1 (de) Verfahren zur überwachung der proteasomeinhibitorarzneimitteleffekte
CY1107733T1 (el) Μεθοδος για τον χαρακτηρισμο μιας βιολογικης καταστασης χρησιμοποιωντας βαθμοnομημενα προφιλ γονιδιακης εκφρασης
HK1079571A1 (en) Methods for direct detection of individual methotrexate metabolites
ATE420204T1 (de) Verfahren zur detektion von erkrankungen
DE602005000485D1 (de) Nukleinsäurenachweisverfahren mittels mehreren Paaren von Donorflurophoren und Quenchemolekülen in derselben Sonde
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
ATE462803T1 (de) Kit und verfahren zum nachweis von urothelkarzinom
DK1882946T3 (da) Fremgangsmåde til at bedømme rheumatold arthritis ved at måle anti-CCP og interleukin 6
NO20052544L (no) Produkt og fremgangsmate.
MX2007010073A (es) Metodo para determinar la respuesta de los inhibidores de chk1.
ATE380346T1 (de) Differentialdiagnose von störungen vom eisenmetabolismus
ATE426168T1 (de) Verwendung von asc als marker fur kolorektalkarzinome
DE50110174D1 (de) Verfahren und testkit zum nachweis von analyten in einer probe
WO2012074550A3 (en) Methods to assess treatment outcomes in reward deficiency syndrome (rds) behaviors utilizing expression profiling
ATE408832T1 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
WO2005040806A3 (en) Use of protein asc as a marker for breast cancer
HUP0303890A2 (hu) Differenciációs nukleinsavak és polipeptidek inhibitorának prosztatarák diagnosztizálására és gyógykezelésére alkalmas expressziós analízise
ATE412180T1 (de) Verfahren und mittel zum nachweis von durch gluten induzierten krankheiten
DE602005024690D1 (de) Verfahren und verbindungen zum nachweis von medizinischen erkrankungen
BRPI0407750B8 (pt) método para detectar a presença de micoplasma em uma amostra de teste, uso de fosfato de acetila ou um seu precursor e/ou fosfato de carbamoíla ou um seu precursor, e, kit para uso na detecção de contaminação por micoplasma